Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Akero Therapeutics

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities4.00%
Size of stake in company3.00%
Market capitalizationUSD 3.8 bn

Sector

Metabolic diseases

Main candidate

Efruxifermin

Main indications

MASH (metabolic dysfunction-associated steatohepatitis)

About the company

Akero Therapeutics is a biotechnology company founded in 2017 and headquartered in San Francisco, California (US), focused on developing treatments for patients with serious metabolic diseases with a high unmet medical need. The company began with an engineered protein called efruxifermin which they have licensed from Amgen. Efruxifermin is in phase III development for the treatment of MASH which is a serious liver disease caused by metabolic dysregulation. Efruxifermin is being evaluated in a phase III program consisting of three clinical trials.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.